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Because  local  anesthetics  are  known  to  inhibit  both  sodium  and  potassium  channels,  and  anesthetic
properties  have  been  attributed  to the  former  effect,  we  compared  their  effects  with  those  of  tetrodotoxin
(TTX),  a  selective  Na+ channel  inhibitor  with  anesthetic  activity,  and  4-aminopyridine  (4-AP),  a selective
potassium  channel  blocker  with  convulsive  activity,  on  transmitter  release  during  rest  and  in  response
to  ﬁeld  (axonal)  stimulation  using  the  microvolume  perfusion  method  and  isolated  prefrontal  cortex
and  spinal  cord  slice  preparations  loaded  with  the radioactive  transmitters  [3H]dopamine  ([3H]DA)  and
[3H]noradrenaline  ([3H]NA).  It is  also  known  that  local  anesthetics  may  exert  analgesic  effect  and,  rarely,
some  adverse  effects  on the  central  nervous  system  (CNS).
Neurochemical  evidence  demonstrated  that  local  anesthetics  administered  at  concentrations  rang-
ing  from  0.5  to  5 mM,  which  might  have  been  intentionally  or accidentally  achieved  in clinical  practice
(e.g.,  during  spinal  and  epidural  anesthesia  or peripheral  nerve  block),  led  to presynaptic  failures  dur-
ing  neurochemical  transmission,  including  inhibited  transmitter  release  associated  with  axonal  ﬁring
and  markedly  enhanced  extraneuronal  concentrations  of transmitters  due  to  increased  resting,  [Ca2+]o-
independent  release.  Tetrodotoxin,  a toxin  with  selective  Na+ channel-blocking  properties,  inhibited  the
stimulation-evoked  release  but failed  to  affect  the  resting  release.  In contrast,  the  potassium  channel
inhibitor  4-AP  enhanced  both  the resting-  and action  potential-evoked  transmitter  releases.  It  is  con-
cluded  that effects  of  local  anesthetics  on  resting  catecholamine  release  in the  spinal  cord  may  contribute
to  their  action  during  neuropathic  pain  relief  and  spinal analgesia  as  well  as  to  their side  effects  in  the
CNS.
©  2016  The  Authors.  Published  by Elsevier  Inc. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Local anesthetics have been widely used in clinical practice for
urgical anesthesia and for short- and long-term pain management,
uch as for treating postoperative and neuropathic pain (Berde and
trichartz, 2010). During spinal and epidural anesthesia neurons
n the dorsal horn are exposed to relatively high concentrations of
ocal anesthetics that diffuse directly into the spinal cord (Bromage
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361-9230/© 2016 The Authors. Published by Elsevier Inc. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
et al., 1963; Berde and Strichartz, 2010) and may  cause adverse
effects, such as convulsions (Agarwal et al., 1992) or cauda equina
syndrome (Rigler et al., 1991).
Although the incidence of adverse effects of local anesthetics has
signiﬁcantly diminished in recent decades (Faccenda and Finucane,
2001) and the permanent toxicity is very rare (0.01–0.07%) (Berde
and Strichartz, 2010; Bouwman and Morre, 2013), transient injuries
do occur. The mechanisms by which local anesthetics exert adverse
effects on the CNS are not well understood (Berde and Strichartz,
2010).
It is generally accepted (van der Wal  et al., 2015) that
local anesthetics (e.g., lidocaine) have anesthetic, analgesic, anti-
inﬂammatory and antihyperalgesic properties mediated by their
inhibitory effects on neuronal Na+ (Scholz, 2002; Lenkey et al.,
2011), and K+ (Wolff et al., 2014) channels. Although it is
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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lso known that both Na+ and K+ channels are involved in
ransmitter release, no study has focused on the effects of local
nesthetics on chemical neurotransmission in the CNS, the frontal
ortex and the spinal cord. Therefore, we studied the release of
opamine and noradrenaline. Both are transmitters in the CNS and,
imilar to other transmitters (e.g., glutamate), are stored in vesi-
les and are released by axonal stimulation-evoked exocytosis in
n external Ca2+ concentration ([Ca2+]o)-dependent manner; thus,
hey serve as an example of any type of transmitter. In addition,
ransmitters can also be released in a [Ca2+]o-independent way
nder resting conditions, when the transmitter mainly released
nto the extraneuronal space results in high concentrations of
atecholamines with long-lasting tonic effects on nonsynaptic
eceptors (Vizi et al., 2010). Therefore, the present study was
esigned to determine the effects of lidocaine and bupivacaine on
he resting and axonal stimulation-evoked release of [3H]dopamine
[3H]DA) and [3H]noradrenaline ([3H]NA) in prefrontal cortex slices
nd the release of [3H]NA in spinal cord slices, as well as to compare
heir actions with those of tetrodotoxin (TTX) and 4-aminopyridine
4-AP), which are selective Na+ and K+ channel inhibitors, respec-
ively.
. Materials and methods
.1. Animal experiments
We  used Wistar (male) rats (120–150 g), and all of the studies
ere conducted in accordance with the principles outlined in the
IH Guidelines for the Care and Use of Laboratory Animals and
ere approved by the local Animal Care Committee at the Institute
f Experimental Medicine, Budapest, Hungary.
.2. Materials
All chemicals were obtained from Tocris Cookson Inc. (Bristol,
K). The radioactive compounds were purchased from American
adiolabeled Chemicals, Inc. (USA) and Perkin Elmer (USA). Lido-
aine HCl (MWt.  270.8) and bupivacaine HCl (MWt.  324.8) were
issolved in Krebs solution; in mM,  NaCl 118, KCl 4.7, CaCl2 1.4,
aHCO3 25, KH2PO4 1.25, MgSO4 1.25, and glucose 11.5.
.3. Measurement of [3H]dopamine and [3H]noradrenaline
elease from prefrontal cortex and spinal cord slices
The release of [3H]DA or [3H]NA from prefrontal cortex
Milusheva et al., 1996) and spinal cord (Nakai et al., 1999)
lices was measured using the microvolume perfusion method
Milusheva et al., 1996). The animals were sacriﬁced under slight
isoﬂurane) anesthesia, their brains were quickly removed, and the
refrontal cortex or spinal cord was dissected. Catecholaminergic
erminals efﬁciently accumulate radiolabeled NA or DA due to the
ctivities of transporters (Moron et al., 2002) located in the pre-
rontal cortex and spinal cord. Prefrontal cortex slices (400 m
hick and 15.8 ± 0.52 mg  in weight, n = 30) and spinal cord sec-
ions at the L6 to S1 level (400 m thick and 13.9 ± 2.9 mg  in
eight, n = 48) were prepared with a McIlwain tissue chopper from
ats weighing 120–150 g. The slices were loaded with levo-[(7,8)-
H]DA (60Ci/mmol and 3 Ci/ml; Amersham) or levo-[7-3H]-NA
15Ci/mmol and 5 Ci/ml) for 45 min  at 37 ◦C in Krebs solution
ontaining 0.3 mM ascorbic acid and 0.03 mM Na2EDTA, and they
ere aerated with a 95% O2 and 5% CO2 gas mixture. After 45 min
f loading, the tissues were transferred to an organ bath with a
.5 ml  capacity, and they were superfused with Krebs solution at a
teady rate of 0.5 ml/min. The efﬂuent was not collected for the ﬁrst
0 min. Subsequently, fractions were collected every 3 min. The
adioactivity remaining in the tissue was measured after perfusionulletin 124 (2016) 21–26
(Milusheva et al., 1996), and we  calculated the amount (neuronal
uptake) of radioactivity at the beginning of the experiments (the
sum of radioactivity released during 19 collection periods and the
radioactivity remaining after perfusion).
In the cerebral cortex samples, 75.2 ± 5.7% (the mean ± SEM
of 30 observations) of the total radioactivity was  accounted for
DA, and 85.6 ± 4.1% (n = 18) was attributed to NA, as measured
by high-pressure liquid chromatography combined with scintilla-
tion spectrometry. For the spinal cord slices 83.6 ± 5.8% (n = 16) of
the radioactivity was released as NA. The remaining radioactivity
was due to metabolites (Milusheva et al., 1996), indicating that the
radioactivity measured in the fractions can be safely attributed to
labeled transmitter release into the perfusion ﬂuid.
The level of radioactivity in the samples (by [3H]DA or [3H]NA
and 3H metabolites) was  determined using a liquid scintillation
counter (Packard 1900 Tri-Carb liquid scintillation spectrometer),
and the counts were converted to absolute activity using exter-
nal standards. The tritium release was expressed in Bq/g and as a
percentage of the amount of radioactivity in the tissue at the time
the release was measured (fractional release, FR%). FRR1 and FRS1
were taken as internal standards (controls) and are indicated in the
ﬁgures. The release of tritium in response to the drug treatment
or ﬁeld (axonal) stimulation was  compared with the basal release
level and was  expressed as the increase in the fractional release of
tritium.
2.4. Nerve stimulation
A 2 Hz electrical ﬁeld stimulation (supramaximal, 2 ms  impulse
duration) was used with a Grass S88 stimulator (Grass Medical
Instrument, Quincy, MA,  USA) through a pair of platinum ring elec-
trodes. A total of 360 or 240 supramaximal shocks were delivered,
as indicated.
2.5. Statistics
Statistical analysis of the data was  performed with a two-tailed
Student t-test and analysis of variance (ANOVA) with Dunnett’s
test. The results are presented as the mean ± SEM. The error bars
in the ﬁgures represent the SEM and were only plotted when they
exceeded the symbol size.
3. Results
3.1. Release of [3H]DA from cerebral cortex slice preparations
In 30 experiments, the prefrontal cortex (PFC) slices contained
220.2 ± 9.5 kBq/g radioactivity following 45 min of loading with
[3H]DA and subsequent washing. Over a 3 min  collection period at
rest, the average release from the second resting samples of the PFC
slices was  1.9 ± 0.1 kBq/g (1.00 ± 0.03% (n = 30) of the total radioac-
tive content). The change in resting release over a 30 min  period
was always compared with the control value (FRR1) determined
during the 3 min  collection period (FRR2/FRR1 = 0.86 ± 0.05, n = 6).
In response to electrical ﬁeld stimulation (2 Hz, 2 ms,  and
360 shocks), the release was  14.0 ± 0.7 kBq/g (n = 30), which was
6.31 ± 0.23% of the radioactivity present in the PFC tissue at the time
of stimulation. When the stimulation (FRS1 = 5.83 ± 0.93%) was
repeated 30 min  after the ﬁrst stimulation (S2), the level of radioac-
tivity released was  5.32 ± 1.33% (FRS2), resulting in an FRS2/FRS1
ratio of 1.04 ± 0.07 (n = 6, Fig. 1a).
When voltage-dependent Na+ inﬂux (i.e., axonal conduc-
tion) was inhibited by the application of TTX (1 M)  between
the ﬁrst and second stimulation, the evoked [3H]DA release
in response to ﬁeld stimulation was  signiﬁcantly blocked
with FRS2/FRS1 = 0.12 ± 0.03 (Fig. 1b). This ﬁnding indicates the
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Fig. 1. The release of [3H]dopamine ([3H]DA) from rat frontal cortex slices. The slices were stimulated two times (S1 and S2), as indicated (supramaximal voltage, 2 ms  impulse
duration, 360 shocks, 2 Hz). The vertical lines represent the SEM. The fractional release (FR% = the percentage of radioactivity in the tissue at the time when the release was
measured) is plotted vs. the fractions collected in 3 min. (a) Control experiments. Note that the radioactivity release in response to ﬁeld stimulations (repeated after 30 min
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nd  maintained in the Krebs perfusion solution as indicated. Note that the stimulat
euronal origin of the released radioactivity. The resting release
as not affected (FRR2/FRR1 = 1.03 ± 0.008).
Epidural anesthetics are administered at concentrations of
.5–2% (lidocaine, 55.2 mM;  bupivacaine, 46.2 mM); anesthetics are
dministered at 1.5–5% for spinal anesthesia and at 1–2% for major
erve blocks. After epidural injection, the spread of the solution into
he tissues of the epidural space is unpredictable (Hogan, 2002),
nd neurons are then exposed to relatively high concentrations
e.g., 5–50 mM)  of local anesthetics. Therefore, we administered
nesthetics at concentrations ranging from 0.1 mM to 5 mM to
est their effects on neurochemical transmission in the CNS. Lido-
aine, at a concentration of 5 mM (Fig. 2c), enhanced the resting
3elease of [ H]DA by more than six-fold, and 1.5 mM bupivacaine
Fig. 2d) increased the release by more than nine-fold. Note that
he stimulation-evoked release was fully inhibited (Fig. 2).
ig. 2. Effects of lidocaine and bupivacaine on the resting and stimulation-evoked releas
wice  (S1 and/or S2), as indicated. Lidocaine or bupivacaine was added to the solution, a
 = 6–6) on the resting and stimulation-evoked release of [3H]dopamine ([3H]DA) express
ncreased by more than six-fold (FRR2/FRR1 = 6.84 ± 0.10), the stimulation-evoked relea
sterisks indicate the level of signiﬁcance, p < 0.01. (d) The effects of bupivacaine (1.5 mM)
[3H]DA). Bupivacaine (1.5 mM)  was added to and maintained in the Krebs solution, as ind
here  was a complete presynaptic deﬁcit in the transmitter release in response to ﬁeld stim
 = 6). The asterisks indicate the level of signiﬁcance, p < 0.01.was  fairly constant (n = 6). (b) Effect of tetrodotoxin (TTX, 1 M).  TTX was  added to
oked release of radioactivity was blocked (n = 6).
When CaCl2 was  removed and EGTA (1 mM), a Ca2+ chelator,
was added to the Krebs solution, 5 mM lidocaine enhanced the
resting release of [3H]DA (FRR2/FRR1 = 5.94 ± 0.34 (n = 4)) (Fig. 3)
to approximately the same extent as that observed in the normal
solution (FRR2/FRR1 = 6.84 ± 0.10) (Fig. 2c). Under the control con-
dition of the removal of Ca2+ from the Krebs solution (1 mM  EGTA
was also added), the axonal stimulation failed to release [3H]DA,
but the resting release was  not affected (data not shown).
4-AP signiﬁcantly increased both the resting
(FRR2/FRR1 = 1.75 ± 0.13, p < 0.05) and axonal ﬁring-associated
(FRS2/FRS1 = 2.52 ± 0.21, p < 0.01) [3H]DA release (Fig. 4a and b).
Our observations are in agreement with previous studies that
have shown that 4-AP increases the release of dopamine in the
brain (King et al., 2012), the release of acetylcholine (Vizi et al.,
1977) and noradrenaline in the heart (Sugimori et al., 1987), and
glutamate from synaptosomes (Tapia and Sitges, 1982).
e of [3H]dopamine ([3H]DA). The slices were stimulated (2 Hz, 360 shocks) once or
s indicated. (a–c) Effect of various concentrations of lidocaine (0.5, 1.5 and 5 mM,
ed as the fractional release (FR%). At 5 mM lidocaine, while the resting release was
se (S1 = 15.2 ±1.8 kBq/g, FRS1 = 6.46 ± 1.04%, n = 6) was  fully inhibited (S2 = 0). The
 on the resting and stimulation (2 Hz, 360 shocks)-evoked release of [3H]dopamine
icated. Note the large increase in [3H]DA release not associated with axonal ﬁring.
ulation (FRR2/FRR1 = 9.40 ± 0.45, S1 = 13710 ± 2684 Bq/g, FRS1 = 6.47 ± 0.35%, S2 = 0,
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Fig. 3. The [Ca2+]o-independent release of [3H]dopamine ([3H]DA) in response to
lidocaine (5 mM)  from frontal cortex slices. Lidocaine was added to the Ca2+-free
(CaCl2 was  omitted and 1 mM EGTA was added) Krebs perfusion solution. The slices
were stimulated (2 Hz, 360 shocks) once (S1 = 12.2 ± 0.6 kBq/g, FRS1 = 5.50 ± 0.44%,
n
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p = 6), as indicated. The asterisks indicate the level of signiﬁcance, p < 0.01.
.2. Release of [3H]NA from cerebral cortex and spinal cord slice
reparations
After the cerebral cortex slices were loaded with [3H]NA,
he average tissue uptake of radioactivity was 435.0 ± 69.8 kBq/g
n = 6). During the collection period (3 min), the fractional release
f radioactivity was 0.89 ± 0.15% (1.9 ± 0.2 kBq/g) at rest. Axonal
timulation (S1) led to the release of 10.9 ± 0.2 kBq/g of radioactivity
Fig. 5a). The effect of lidocaine on the resting release depended on
he concentration. The FRR2/FRR1 values were 0.85 ± 0.02 (p > 0.05,
 = 5), 1.87 ± 0.10 (p < 0.05, n = 5) and 2.53 ± 0.20 (p < 0.01, n = 6) at
oncentrations of 0.1, 1.5 and 3 mM,  respectively. At a concentra-
ion of 3 mM,  lidocaine signiﬁcantly enhanced the resting release
nd reduced the stimulation-evoked release of [3H]NA (Fig. 5b).
In clinical practice, solutions of 0.5% lidocaine (18.4 mM)  and
upivacaine (15.4 mM)  that are locally injected into spinal space
ight result in relatively high local concentrations of these drugs.
herefore, we also studied the effect of lidocaine on [3H]NA release
rom the spinal cord slices (Fig. 6a). After 45 min  of loading, the
issue contained 283.6 ± 50.4 kBq/g of radioactivity (n = 14). At
est, 0.7 ± 0.05% of the radioactive content was released during
he 3 min  collection period. Electrical ﬁeld stimulation released
3H]NA from the preparations (FRS1 = 7.4 ± 0.9 kBq/g, n = 6) and the
RS2/FRS1 was 0.91 ± 0.08 (n = 6). At a concentration of 5 mM,  lido-
aine enhanced the resting release and completely blocked the
timulation-evoked release (Fig. 6a). 4-Aminopyridine (300 M)
nhanced both the resting and stimulation-evoked release (Fig. 6b).
ig. 4. Effect of 4-aminopyridine (4-AP) on the release of [3H]dopamine ([3H]DA) from the 
sterisks indicate p < 0.01. (a) 4-Aminopyridine was added at a concentration of 100 M. Tw
 = 5). (b) 4-Aminopyridine at a concentration of 300 M increased both the resting (FRR2/F
 < 0.01) of [3H]dopamine (n = 6). (S1 15.6 ± 0.7 kBq/g, FRS1 = 6.44 ± 0.07%).ulletin 124 (2016) 21–26
Tetrodotoxin (1 M)  fully inhibited the stimulation-evoked release
(data not shown).
4. Discussion
We  have shown that local anesthetics (lidocaine and bupiva-
caine) at concentrations > 0.5 mM produced a partial or complete
dissociation of chemical neurotransmission, i.e., reduced or inhib-
ited neuronal stimulation-evoked, [Ca2+]o-dependent release and
increased [Ca2+]o-independent resting release of [3H]DA and
[3H]NA from frontal cortex slices and [3H]NA release from spinal
cord slices. To the best of our knowledge, our study is the ﬁrst
to provide neurochemical evidence that local anesthetics enhance
transmitter release at rest (Fig. 2b–d). The selective K+ chan-
nel inhibitor 4-AP also enhanced the resting transmitter release,
which is independent of the axonal activity and induces clonic
and tonic seizures in patients (King et al., 2012). However, while
local anesthetics partially or fully inhibit it, 4-AP potentiates
stimulation-evoked release from prefrontal cortex (Fig. 4) and
spinal cord preparations (Fig. 6b). Therefore, we  suggest that
the rare occurrence of adverse effects to local anesthetics is due
to their effects on chemical transmission inﬂuenced by com-
bined inhibitory effects on Na+ and K+ channels inhibiting the
stimulation–evoked (an effect on Na+ channels) and enhancing the
resting release of catecholamines (an effect on K+ channels). This
conclusion is strongly supported by the ﬁndings that diazoxide, a K+
channel opener reduces both the resting and stimulation-evoked
release of noradrenaline (Takata et al., 1992; Oe et al., 1999); in
addition, pinacidil, a drug with a similar effect on K+ channels, has
been shown to inhibit the stimulation-induced release of endoge-
nous dopamine and noradrenaline (Soares-da-Silva and Fernandes,
1990). Tetrodotoxin, a selective Na+ channel blocker (Narahashi,
1972; Kohane et al., 1998) with local anesthetic activity (Padera
et al., 2006), fully inhibited the [Ca2+]o-dependent release of trans-
mitters evoked by axonal stimulation in both preparations. TTX is
similar to local anesthetics in this respect, it is even able to poten-
tiate the action of local anesthetics (Kohane et al., 1998; Padera
et al., 2006), but it failed to affect the [Ca2+]o-independent release
of [3H]DA at rest and does not cause adverse CNS effects after sys-
temic administration (Marcil et al., 2006). TTX has no inhibitory
effect on K+ permeability.
Voltage-gated sodium channels are the pharmacological tar-
gets of a variety of drugs, such as analgesics, local anesthetics,
antiarrhythmics and antiepileptics (Lenkey et al., 2010, 2011).
Presynaptic potassium channels play a key role in cellular phys-2015). It is known that local anesthetics are also able to inhibit
K+ channels (Scholz, 2002; Wolff et al., 2014) in neocortical
rat prefrontal cortex slices. The tissues were stimulated twice (2 Hz, 360 shocks). The
o stimulations were applied as indicated (S1 = 15.9 ± 1.1 kBq/g, FRS1 = 5.96 ± 0.63%,
RR1 = 2.68 ± 0.03, p < 0.01) and stimulation-evoked release (FRS2/FRS1 = 3.50 ± 0.20,
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Fig. 5. Effect of lidocaine (3 mM)  on the resting and stimulation-evoked release of [3H]noradrenaline ([3H]NA) from rat prefrontal cortex slices. The slices were stimu-
lated  twice (2 Hz, 360 shocks) (S1 and S2), as indicated. R1 and R2 are also indicated. (a) Control experiments. Resting (FRR2/FRR1 = 0.93 ± 0.06) and stimulation-evoked
(FRS2/FRS1 = 0.89 ± 0.12) release were relatively constant (n = 6). (b) The effect of lidocaine (3 mM)  on the resting (FRR2/FRR1 = 2.53 ± 0.20 compared with the control
(0.93  ± 0.06) p < 0.01)) and stimulation-evoked release of [3H]noradrenaline (S1 = 16.2 ± 2.3 kBq/g (n = 5). (FRS2/FRS1 = 0.54 ± 0.07, compared with the control (0.89 ± 0.12)
p  < 0.01). Notably, lidocaine enhanced the resting release, but reduced the stimulation-evoked release.
Fig. 6. Effects of lidocaine (5 mM)  and 4-aminopyridine (300 M)  on the release of [3H]noradrenaline ([3H]NA) from in vitro rat spinal cord slice preparations. The slices
were  stimulated (3 Hz, 240 shocks) twice (S1 and S2) as indicated. Fractions were collected every 3 min. The release is expressed as the% fractional release (FR) n = 6–6. The
asterisks indicate p < 0.01. (a) Lidocaine (5 mM)  signiﬁcantly enhanced the resting release (asterisks indicate p < 0.01) of [3H]NA (FRR2/FRR1 = 5.22 ± 0.20, p < 0.001). Note that
ﬁeld  stimulation (S2) failed to enhance the release to the same extent. S1 = 6.3 ± 0.9 and S2 = 3.2 ± 0.8 kBq/g. (b) Effect of 4-aminopyridine (300 M)  on the release of [3H]NA.
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1 = 6.9 ± 0.9 kBq/g, S2 = 17.4 ± 2.5 (n = 4).
Andreasen and Hablitz, 1993) and dorsal horn (Olschewski et al.,
998) neurons. Since a variety of K+ currents are known to be
nvolved in the repolarization of the neuron action potential, any
ffect on K+ channels may  inﬂuence transmitter release.
It is notable that locally applied anesthetics (0.5–5% w/v, which
s 15.4–154 mM for bupivacaine) that penetrate the tissue can eas-
ly result in local concentrations of >0.5 mM that are required to
evelop the local anesthetic effect (Schmidtmayer and Ulbricht,
980); these concentrations are also sufﬁciently high to affect
ransmitter release, as observed in this study.
Subarachnoid injection of a local anesthetic (lidocaine, 75 mg)
roduces anesthesia lasting from 60 to 115 min  (Moore et al., 1987).
t has been shown that the volume (42–81 ml)  of lumbosacral cere-
rospinal ﬂuid is the primary determinant of sensory block extent
nd duration (Higuchi et al., 2004). Accordingly, 75 mg  of lidocaine
dministered into the lumbosacral cerebrospinal ﬂuid (∼60 ml)
ight produce a 4–5 mM concentration, high enough to affect
ransmitter release. Continuous spinal anesthesia even with a rel-
tively lower concentration that is increasingly administered over
 long time period to treat postoperative neuropathic pain (Berde
nd Strichartz, 2010) also increases the chance of neurotoxicity.
It has been shown that dopaminergic (Cobacho et al., 2014)
nd noradrenergic (Takano and Yaksh, 1992) mechanisms are
nvolved in the antiallodynic action of neuropathic pain; therefore,
he release of NA in response to a spinal administration of local
nesthetics is very likely involved in the pain-relief action. This
onclusion is supported by the fact that the descending noradrener-
ic system originating from brainstem nuclei A5, A6 and A7 exerts17, p < 0.001 and markedly potentiated the stimulation-evoked release of [ H]NA.
analgesia by inhibiting glutamate release from the spinal nocicep-
tive primary afferent ﬁber (Kamisaki et al., 1993), which is an effect
that can be blocked by 2-adrenoceptor antagonists (Takano and
Yaksh, 1992). Indeed, clinically, intrathecal and epidural admin-
istration of 2-adrenoceptor agonists (e.g., clonidine), drugs that
are able to mimic  the effect of NA with an agonist effect on these
2-adrenoceptors, have been used for spinal analgesia for the treat-
ment of intractable pain (Rauck et al., 1993).
Local anesthetics increase the release of [3H]NA or
[3H]DA at rest, resulting in a high ambient concentration
of catecholamines and their toxic aldehyde metabolites
(3,4-dihydroxyphenylacetaldehyde (DOPAL) and 3,4-
dihydroxyphenylglycolaldehyde (DOPEGAL)) (Burke et al., 2004);
these effects might also be involved in neurotoxic effects.
In clinical practice, an overdose, accidental rapid injection or
local administration of a local anesthetic may  produce adverse
effects in the nervous system. An interesting problem that remains
to be studied is how patients suffering from different soma-
dendritic and axo-somatic channelopathies (Brager and Johnston,
2014) or being treated with noradrenaline uptake blockers may
respond to local anesthetics. Nevertheless, although neurotoxicity
from local anesthetics occurs very rarely, it may  limit their clinical
utility, and, at a minimum, caution should be exercised in selecting
the volume, total dose and concentration of a speciﬁc anesthetic.Declaration of interest
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